Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2006 2
2008 2
2009 1
2010 1
2012 2
2013 1
2020 1
2022 3
2023 0
Text availability
Article attribute
Article type
Publication date

Search Results

12 results
Results by year
Filters applied: . Clear all
Page 1
Improving the EHMRG Prognostic Evaluation of Acute Heart Failure with TAPSE/PASp: A Sequential Approach.
Falsetti L, Zaccone V, Viticchi G, Fioranelli A, Diblasi I, Guerrieri E, Ferrini C, Scarponi M, Giuliani L, Scalpelli C, Martino M, Pansoni A, Luccarini M, Burattini M, Moroncini G, Tarquinio N. Falsetti L, et al. Among authors: burattini m. Diagnostics (Basel). 2022 Feb 13;12(2):478. doi: 10.3390/diagnostics12020478. Diagnostics (Basel). 2022. PMID: 35204569 Free PMC article.
Implementation of EHMRG Risk Model in an Italian Population of Elderly Patients with Acute Heart Failure.
Falsetti L, Zaccone V, Guerrieri E, Perrotta G, Diblasi I, Giuliani L, Palma LEG, Viticchi G, Fioranelli A, Moroncini G, Pansoni A, Luccarini M, Martino M, Scalpelli C, Burattini M, Tarquinio N. Falsetti L, et al. Among authors: burattini m. J Clin Med. 2022 May 25;11(11):2982. doi: 10.3390/jcm11112982. J Clin Med. 2022. PMID: 35683368 Free PMC article.
Clusters of Comorbidities in the Short-Term Prognosis of Acute Heart Failure among Elderly Patients: A Retrospective Cohort Study.
Falsetti L, Viticchi G, Zaccone V, Guerrieri E, Diblasi I, Giuliani L, Giovenali L, Gialluca Palma LE, Marconi L, Mariottini M, Fioranelli A, Moroncini G, Pansoni A, Burattini M, Tarquinio N. Falsetti L, et al. Among authors: burattini m. Medicina (Kaunas). 2022 Oct 5;58(10):1394. doi: 10.3390/medicina58101394. Medicina (Kaunas). 2022. PMID: 36295555 Free PMC article.
Low-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed/refractory multiple myeloma: a prospective, multicenter, phase II study.
Offidani M, Corvatta L, Marconi M, Visani G, Alesiani F, Brunori M, Galieni P, Catarini M, Burattini M, Centurioni R, Rupoli S, Scortechini AR, Giuliodori L, Candela M, Capelli D, Montanari M, Olivieri A, Piersantelli MN, Leoni P. Offidani M, et al. Among authors: burattini m. Haematologica. 2006 Jan;91(1):133-6. Haematologica. 2006. PMID: 16434383 Clinical Trial.
Thalidomide-dexamethasone versus interferon-alpha-dexamethasone as maintenance treatment after ThaDD induction for multiple myeloma: a prospective, multicentre, randomised study.
Offidani M, Corvatta L, Polloni C, Piersantelli MN, Gentili S, Galieni P, Visani G, Alesiani F, Catarini M, Brunori M, Samori A, Burattini M, Centurioni R, Ferranti M, Giuliodori L, Candela M, Mele A, Marconi M, Leoni P. Offidani M, et al. Among authors: burattini m. Br J Haematol. 2009 Mar;144(5):653-9. doi: 10.1111/j.1365-2141.2008.07495.x. Epub 2008 Nov 13. Br J Haematol. 2009. PMID: 19036082 Free article. Clinical Trial.
Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma.
Offidani M, Corvatta L, Piersantelli MN, Visani G, Alesiani F, Brunori M, Galieni P, Catarini M, Burattini M, Centurioni R, Ferranti M, Rupoli S, Scortechini AR, Giuliodori L, Candela M, Capelli D, Montanari M, Olivieri A, Poloni A, Polloni C, Marconi M, Leoni P. Offidani M, et al. Among authors: burattini m. Blood. 2006 Oct 1;108(7):2159-64. doi: 10.1182/blood-2006-03-013086. Epub 2006 Jun 8. Blood. 2006. PMID: 16763209 Free article. Clinical Trial.
Assessment of vulnerability measures and their effect on survival in a real-life population of multiple myeloma patients registered at Marche Region Multiple Myeloma Registry.
Offidani M, Corvatta L, Polloni C, Centurioni R, Visani G, Brunori M, Gentili S, Catarini M, Samori A, Blasi N, Alesiani F, Caraffa P, Burattini M, Galieni P, Fraticelli P, Ferranti M, Giuliodori L, Leoni P. Offidani M, et al. Among authors: burattini m. Clin Lymphoma Myeloma Leuk. 2012 Dec;12(6):423-32. doi: 10.1016/j.clml.2012.06.008. Epub 2012 Sep 14. Clin Lymphoma Myeloma Leuk. 2012. PMID: 22981966
Serum C-reactive protein at diagnosis and response to therapy is the most powerful factor predicting outcome of multiple myeloma treated with thalidomide/ anthracycline-based therapy.
Offidani M, Corvatta L, Polloni C, Piersantelli MN, Galieni P, Visani G, Alesiani F, Catarini M, Brunori M, Burattini M, Centurioni R, Ferranti M, Giuliodori L, Candela M, Mele A, Marconi M, Leoni P. Offidani M, et al. Among authors: burattini m. Clin Lymphoma Myeloma. 2008 Oct;8(5):294-9. doi: 10.3816/CLM.2008.n.041. Clin Lymphoma Myeloma. 2008. PMID: 18854284
12 results